Celgene Overview
- Founded
-
1986

- Status
-
Acquired/Merged
- Employees
-
8,800

- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$80.3B
Celgene General Information
Description
Developer of biopharmaceutical drugs intended to treat cancer, immune and inflammatory conditions. The company markets drugs to treat multiple myeloma and a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Acquirer
Primary Office
- 86 Morris Avenue
- Summit, NJ 07901
- United States
Celgene Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Merger/Acquisition | 20-Nov-2019 | $80.3B | 000.00 | 000.00 | Completed | Profitable |
3. PIPE | 000.00 | Completed | Profitable | |||
2. IPO | 28-Jul-1987 | $12.7M | $12.7M | Completed | Generating Revenue | |
1. Early Stage VC | 01-Jan-1986 | Completed | Generating Revenue |
Celgene Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of biopharmaceutical drugs intended to treat cancer, immune and inflammatory conditions. The company markets d
Drug Discovery
Summit, NJ
8,800
As of 2021
000.00
00.00
0000-00-00
000000&0
000.00
Celgene Competitors (28)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Intas Pharmaceuticals | Private Equity-Backed | Ahmedabad, India | 00000 | 000.00 | 00000000000 | 000.00 |
000000 00000000 | Formerly VC-backed | Foster City, CA | 00000 | 00.000 | 000000000 | 00.000 |
00000 | Corporation | Basel, Switzerland | 000000 | 00.000 | 00000000000 | 00.000 |
000000 000000 000 | Private Equity-Backed | Mumbai, India | 0000 | 00000000000 | ||
000000 0000 000000 | Formerly VC-backed | Torrance, CA | 00 | 000.00 | 000000000 - | 000.00 |
Celgene Patents
Celgene Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20230028747-A1 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | Pending | 16-Jun-2021 | 0000000000 | |
US-20220387405-A1 | Methods of treatment with n-((r)-1-(3-chloropyridin-2-yl)-2,2,2-trifluoroethyl)-2-((s)-2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-carboxamide | Pending | 06-May-2021 | 0000000000 | |
US-20220401569-A1 | Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi) | Pending | 30-Apr-2021 | 00000000000 | |
EP-4121051-A1 | Combination therapy for acute myeloid leukemia | Pending | 12-Mar-2021 | ||
US-20220265618-A1 | Methods of treating prostate cancer | Pending | 22-Feb-2021 | A61K31/438 |
Celgene Board Members (21)
Name | Representing | Role | Since |
---|---|---|---|
Hans Bishop | Self | Board Member | 000 0000 |
Michael Casey | Celgene | Board Member | 000 0000 |
Rodman Drake | Celgene | Board Member | 000 0000 |
Celgene Signals
Celgene Former Investors (5)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Asseily Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
BB Biotech | Asset Manager | Minority | 000 0000 | 000000 0 | |
CHL Medical Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Edelson Technology Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Ridgeback Capital | Venture Capital | Minority | 000 0000 | 000000 0 |
Celgene Investments & Acquisitions (127)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000 | 07-Jan-2020 | 00000 0000 | 0000 | Decision/Risk Analysis | |
0000000 | 20-Dec-2019 | 00000 0000 | 000.00 | Drug Discovery | |
000000 000000 | 15-Oct-2019 | 00000 0000 | 000.00 | Drug Discovery | 00000 000 |
0000000 | 11-Sep-2019 | 00000 0000 | 000.00 | Drug Discovery | |
RAPT Therapeutics | 18-Jun-2019 | Later Stage VC | 0000 | Drug Discovery |
Celgene Subsidiaries (2)
Company Name | Industry | Location | Founded |
---|---|---|---|
Acetylon Pharmaceuticals | Drug Discovery | Boston, MA | 2008 |
0000000000000 | Biotechnology | Gaithersburg, MD | 0000 |
Celgene Exits (70)
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
0000000 | 20-Dec-2019 | 00000 00000 00 | 000.00 | Completed |
|
000000 00000000000 | 15-Oct-2019 | 00000 00000 00 | 000.00 | Completed |
|
0000 000000000000 | 18-Jun-2019 | 00000 00000 00 | 0000 | Completed |
|
0000000000 | 10-May-2019 | 00000 | 0000 | Completed |
|
Vividion Therapeutics | 30-Apr-2019 | Later Stage VC | 0000 | Completed |
|